Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth Jun 30, 2025
Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares Apr 30, 2025
Iterum Therapeutics Presented a Scientific Poster at ECCMID 2025 Highlighting the Impact of Age on Antibiotic Resistance and Efficacy of Antibiotics Apr 14, 2025
